Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Core Insights - Samsung Bioepis and Epis NexLab have signed a research collaboration and license agreement with G2GBIO to develop novel assets, including long-acting semaglutide, utilizing G2GBIO's proprietary microsphere technology [1][1][1] Group 1: Agreement Details - Samsung Bioepis will receive exclusive licensing rights for the long-acting semaglutide asset and an option to license another asset from G2GBIO [1][1] - The agreement includes first negotiation rights for three additional novel assets to be determined [1][1] - Epis NexLab will co-develop the long-acting microsphere drug delivery platform using G2GBIO's technology [1][1] Group 2: Company Background - Samsung Bioepis, established in 2012, is a biopharmaceutical company focused on making healthcare accessible through innovative product development [1][1] - The company aims to become a leading biopharmaceutical entity with a broad pipeline covering various therapeutic areas, including immunology, oncology, and endocrinology [1][1]